L
Lisa Elkin
Researcher at Bristol-Myers Squibb
Publications - 11
Citations - 262
Lisa Elkin is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Cancer & Angiogenesis inhibitor. The author has an hindex of 7, co-authored 11 publications receiving 218 citations.
Papers
More filters
Journal ArticleDOI
Drug-Induced Perturbations of the Bile Acid Pool, Cholestasis, and Hepatotoxicity: Mechanistic Considerations beyond the Direct Inhibition of the Bile Salt Export Pump
TL;DR: The bile salt export pump (BSEP) is located on the canalicular plasma membrane of hepatocytes and plays an important role in the biliary clearance of bile acids (BAs), so screening compounds in a discovery setting or conducting mechanistic studies to address clinical findings must consider the direct (inhibitory) effect of the parent drug and metabolites on multiple BA transporters.
Journal ArticleDOI
Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain *
John S. Tokarski,Adriana Zupa-Fernandez,Jeffrey Tredup,Kristen Pike,Chiehying Chang,Dianlin Xie,Lihong Cheng,Donna L. Pedicord,Jodi K. Muckelbauer,Stephen R. Johnson,Sophie Wu,Suzanne C. Edavettal,Yang Hong,Mark R. Witmer,Lisa Elkin,Yuval Blat,William J. Pitts,David S. Weinstein,James R. Burke +18 more
TL;DR: The results support a model where the pseudokinase domain regulates activation of the catalytic domain by forming receptor-regulated inhibitory interactions, and represent a novel approach to the design of potent and selective agents for the treatment of autoimmunity.
Journal ArticleDOI
Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
Scott A. Mitchell,Mihaela Diana Danca,Peter Blomgren,James W. Darrow,Kevin S. Currie,Kropf Jeffrey E,Seung H. Lee,Steven L. Gallion,Jin-Ming Xiong,Douglas A. Pippin,Robert Desimone,David R. Brittelli,David C. Eustice,Aaron Bourret,Melissa Hill-Drzewi,Patricia Maciejewski,Lisa Elkin +16 more
TL;DR: A novel series of imidazo[1,2-a]pyrazine diarylureas that show nanomolar potency for the EphB4 receptor, in addition to potent activity against several other RTKs are reported.
Journal ArticleDOI
Identification and optimization of a novel series of indoleamine 2,3-dioxygenase inhibitors
Jay A. Markwalder,Steven P. Seitz,Yuval Blat,Lisa Elkin,John T. Hunt,Jonathan G. Pabalan,Maria Jure-Kunkel,Gregory D. Vite,Kelly L. Covello +8 more
TL;DR: Optimization of a micromolar hit through iterative cycles of synthesis and screening in an assay measuring IDO-mediated intracellular conversion of tryptophan to kynurenine led to potent inhibitors with favorable selectivity and metabolic stability profiles.
Book ChapterDOI
Challenges and Opportunities in Enabling High-Throughput, Miniaturized High Content Screening.
Debra Nickischer,Lisa Elkin,Normand J. Cloutier,Jonathan O’Connell,Martyn Banks,Andrea D. Weston +5 more
TL;DR: The infrastructure developed and applied at Bristol-Myers Squibb for 1536-well high content screening is outlined and key lessons learned are discussed, including how to interpret the large volumes of content-rich information generated.